Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | GALR3 | O60755 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | CPT2 | P23786 | 1/20 | 0.38 |
| ▸ | CPT1A | P50416 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL6748621 | 0.97 | MAPT (0.44) | MAPTSLC22A16TSHRCHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL9486928 | 0.97 | MAPT (0.50) | MAPTSLC22A16TSHRCHRM2CHRM4 | |
| Dimethylcarbate SCHEMBL8064789 | 0.85 | SLC22A16 (0.45) | MAPTSLC22A16TSHRCHRM2CHRM4 | |
| SCHEMBL29574838 | 0.82 | TSHR (0.40) | MAPTSLC22A16TSHRCHRM2CHRM4 | |
| SCHEMBL2269116 | 0.77 | CHRM2 (0.45) | MAPTSLC22A16TSHRCHRM2CHRM4 | |
| SCHEMBL675895 | 0.76 | LMNA (0.46) | MAPTSLC22A16TSHRCHRM2CHRM4 | |
| SCHEMBL5582502 | 0.76 | MAPT (0.44) | MAPTSLC22A16TSHRCHRM2CHRM4 | |
| SCHEMBL21220027 | 0.75 | MAPT (0.40) | MAPTSLC22A16TSHRCHRM2CHRM4 | |
| SCHEMBL718907 | 0.75 | SLC22A16 (0.45) | MAPTSLC22A16TSHRCHRM2CHRM4 | |
| SCHEMBL2303832 | 0.74 | MAPT (0.43) | MAPTSLC22A16TSHRCHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 457 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3762716-B1 | A PROTEIN-BINDING PRODUCT, A DEVICE CONTANING SAID PROTEIN-BINDING PRODUCT AND A METHOD FOR EXTRACORPOREAL REDUCTION OF THE LEVEL OF PROTEIN IN BLOOD PLASMA | GLYCOREX TRANSPLANTATION AB (SE) | 2026-05-06 | — | — | EP | claimed |
| EP-3538001-B1 | LED ASSISTED WOUND HEALING SYSTEM | THE BIOREGENTECH INST INC (US) | 2026-01-14 | — | — | EP | claimed |
| EP-4635491-A1 | COMPOSITION COMPRISING A CARRIER AND EITHER SODIUM CHLORIDE OR POTASSIUM CHLORIDE, AND APPLICATOR WITH A PRESSURE APPLICATION UNIT FOR APPLYING THE COMPOSITION AND SET OF A FIRST AND SECOND APPLICATOR | Gemeinschaftspraxis für Physiotherapie GbR (vertretungsberechtigte Gesellschafter: Natalie Morell und Nils Morell) (DE) | 2025-10-22 | — | — | EP | claimed |
| EP-3876904-B1 | ORAL MUCOSAL CARRIER AND PROTECTANT | INSPIRED MAT STRATEGIES LLC (US) | 2025-08-20 | — | — | EP | claimed |
| EP-3815674-B1 | COMPOSITION FOR MUSCLE RELAXATION | CAREGEN CO LTD (KR) | 2025-08-13 | — | — | EP | claimed |
| EP-4337029-B1 | A FOOD SUPPLEMENT FOR USE AS COADJUVANT IN THE PREVENTION AND TREATMENT OF COGNITIVE DECLINE ASSOCIATED WITH ALZHEIMER DISEASE | CRISTALFARMA S R L (IT) | 2025-06-18 | — | — | EP | claimed |
| EP-3230302-B1 | CARRIER MOLECULE COMPOSITIONS AND RELATED METHODS | JYSK SKIN SOLUTIONS PTE LTD (SG) | 2025-04-30 | — | — | EP | claimed |
| CN-119656222-A | Use of a composition | 羲祚(上海)生物科技有限责任公司 | 2025-03-21 | — | — | CN | claimed |
| WO-2025040605-A1 | OPHTHALMOLOGICAL COMPOSITION CONTAINING AT LEAST ONE NICOTINIC ACETYLCHOLINE RECEPTOR MODULATOR FOR TOPICAL ADMINISTRATION TO THE EYE FOR PREVENTING OR TREATING INFLAMMATION OF THE EYE | URSAPHARM ARZNEIMITTEL GMBH (DE) | 2025-02-27 | — | — | WO | claimed |
| EP-3655036-B1 | COMPOSITIONS FOR TREATING STRESS-RELATED DISORDERS | HOFFMAN TECH LLC (US) | 2024-09-04 | — | — | EP | claimed |
| EP-1828779-A2 | METHOD FOR IDENTIFYING MODULATORS OF THE ACTIVITY OF ION-CHANNELS RECEPTORS | Centre National de la Recherche Scientifique - CNRS (FR) | 2007-09-05 | — | — | EP | claimed |
| WO-2007048459-A1 | CELL-FREE IN VITRO TRANSCRIPTION AND TRANSLATION OF MEMBRANE PROTEINS INTO TETHERED PLANAR LIPID LAYERS | Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2007-05-03 | — | — | WO | claimed |
| WO-2006064372-A9 | METHOD FOR IDENTIFYING MODULATORS OF THE ACTIVITY OF ION-CHANNELS RECEPTORS | CENTRE NAT RECH SCIENT (FR) | 2006-11-16 | — | — | WO | claimed |
| WO-2006064372-A2 | METHOD FOR IDENTIFYING MODULATORS OF THE ACTIVITY OF ION-CHANNELS RECEPTORS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2006-06-22 | — | — | WO | claimed |
| EP-1641488-A1 | EPITOPE COMPOSITION FOR SUBLINGUAL, BUCCAL OR ENTERIC ADMINISTRATION PREPARED BY HYDROLYSIS OF ANTIGENIC STRUCTURES WITH CHYMOTRYPSIN | BioTech Tools S.A. (BE) | 2006-04-05 | — | — | EP | claimed |
| US-20060062859-A1 | Composition and method to optimize and customize nutritional supplement formulations by measuring genetic and metabolomic contributing factors to disease diagnosis, stratification, prognosis, metabolism, and therapeutic outcomes | KENBER RESEARCH, LLC | 2006-03-23 | — | — | US | claimed |
| WO-2004112833-A1 | EPITOPE COMPOSITION FOR SUBLINGUAL, BUCCAL OR ENTERIC ADMINISTRATION PREPARED BY HYDROLYSIS OF ANTIGENIC STRUCTURES WITH CHYMOTRYPSIN | BIOTECH TOOLS SA (BE) | 2004-12-29 | — | — | WO | claimed |
| WO-1999034678-A1 | LOCUST CONTROL | BAYER AKTIENGESELLSCHAFT (DE) | 1999-07-15 | — | — | WO | claimed |
| EP-0537229-A1 | RECEPTOR DIRECTED-TOXIN CONJUGATES | Akzo Nobel N.V. (NL) | 1993-04-21 | — | — | EP | claimed |
| WO-1992000762-A1 | RECEPTOR DIRECTED-TOXIN CONJUGATES | AKZO N.V. (NL) | 1992-01-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060062859-A1 | Composition and method to optimize and customize nutritional supplement formulations by measuring genetic and metabolomic contributing factors to disease diagnosis, stratification, prognosis, metabolism, and therapeutic outcomes | SLC5A6, SLC46A1, CYP24A1 | MAPT 2308/4885SLC22A16 21/4885TSHR 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.